• Sort Order

  • Media Outlet

  • Reset

Copay assistance: Doing more harm than good?

Copay assistance: Doing more harm than good?

Dr. Peter Bach discusses how copay assistance programs are actually causing drug prices to rise on Closing Bell.

Go To Link
Drug Coupons: Helping a Few at the Expense of Everyone

Drug Coupons: Helping a Few at the Expense of Everyone

Margot Sanger-Katz reports on the negative effects of drug coupons, citing a paper written by Dr. Peter Ubel and Dr. Peter Bach that outlines the issue and prescribes policy solutions

Go To Link
Value Tools at ASCO 2016: Building a Framework for Prime Time

Value Tools at ASCO 2016: Building a Framework for Prime Time

Lynne Lederman reports on the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting wasCollective Wisdom: The Future of Patient-Centered Care and Research discussion on value frameworks, as well as the results of a value survey conducted during and after ASCO by ZS in collaboration with WebMD that was completed by 93 medical or hematologic oncologists who practice in community or academic settings.

Go To Link
Two-year extenders deal looming?

Two-year extenders deal looming?

Well, we found some bipartisan agreement about the big tax extenders deal on Monday — though not the sort of consensus that many had hoped for: Leaders in both parties are starting to sound a whole lot less optimistic.

Go To Link
Master of health care delivery science connects alumni with web seminars

Master of health care delivery science connects alumni with web seminars

The College’s master of health care delivery science program currently reconnects its students, alumni and staff by offering virtual seminars on a wide variety of topics.

Go To Link
A Q&A with Peter Bach

A Q&A with Peter Bach

Peter Bach, MD, MAPP, director, Center for Health and Policy Research, Memorial Sloan Kettering Cancer Center, speaks about DrugAbacus, the importance of using value frameworks, and using the European market as a model to recalibrate the healthcare system in the United States.

Go To Link
Expensive Oral Agents Responsible for Cost Shifting in Cancer

Expensive Oral Agents Responsible for Cost Shifting in Cancer

Oral anticancer agents are being launched at significantly higher prices compared with a decade ago, which can prove a barrier to patient access, according to a new analysis published in JAMA Oncology.

Go To Link
The Insurance Companies’ Latest Target: Specialty Drugs

The Insurance Companies’ Latest Target: Specialty Drugs

Read the headlines these days and you’d think the health insurance companies are going broke.

Go To Link
What Is Coming in Specialty Pharmacy? A Look at the Near-Term Drug Pipeline

What Is Coming in Specialty Pharmacy? A Look at the Near-Term Drug Pipeline

AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016 kicked off by delving into the near-term specialty pharmaceutical pipeline with Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts.

Go To Link
Dr Steve Miller Highlights the Importance of Working Closely With Oncologists

Dr Steve Miller Highlights the Importance of Working Closely With Oncologists

Working closely with oncologists on value assessment frameworks can save money for the healthcare system while guaranteeing great outcomes for patients, Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, said during a pre-meeting session of AMCP Managed Care & Specialty Pharmacy Annual Meeting 2016. –

Go To Link